Spanish cosmetic actives maker Vytrus Biotech has obtained a US patent relating to wound-healing applications in its product portfolio.
The patent granted by the United States Patent and Trademark Office, ‘Cell-free plant cell culture suspension supernatant with re-youth activity and/or wound healing activity over skin cells’, is valid until 11 March 2038.
The patent covers the Clarivine and Centella Reversa actives in the Vytrus portfolio, specifically for skin wound healing applications.
These products are rich in plant peptides, as well as natural plant exosomes, molecules that are highly demanded by the dermocosmetic market globally for their multiple skin care benefits.
Launched in April, Clarivine is a 100% natural biotechnological active ingredient based on vine stem cells.
It introduces an innovative approach in cosmetics to promote skin longevity and a ‘glass skin’ by mimicking the effects of intermittent fasting on skin cells.
This is the second recognition that Barcleona company has received from the intellectual property authorities of the US, which is its main market after Europe.
The biotech company's sales in the US grew by 27% during the first three months of the year compared to Q1 2024.
